Thyroid nodule and autoimmune thyroid disease frequency in adults with inborn errors of immunity: a case-control study Authors: Zeliha Yarar, Mehmet Emin Gerek, Fatih Çölkesen, Şevket Arslan, Feridun Karakurt Published: 2026 ABSTRACT BackgroundInborn errors of immunity (IEIs) are defined by impaired immune function and abnormal immune system development. The recognition of significant interactions between the immune and endocrine systems has emerged as an area of growing clinical interest. The study aimed to evaluate the frequency of thyroid nodules and autoimmune thyroid diseases in patients with IEIs.Materials and methodsThis study included 40 IEI patients and 65 healthy subjects as control group. Demographic and clinical data were collected from medical records. All participants underwent thyroid ultrasound and biochemical evaluation for thyroid function tests and autoantibody levels. The diagnosis of autoimmune thyroid disease (AITD) diagnosis was based on thyroid specific autoantibody levels, thyroid function tests, and/or ultrasonographic features consistent with thyroiditis.ResultsThyroid nodules were detected in 5 patients (12.5%) in the IEI group and in 14 subjects (21.5%) in the control group, with no statistically significant difference in thyroid nodule frequency between the two groups (p = 0.243). AITD was significantly more prevalent in the IEI group compared to controls (45.0% vs. 23.1%; p = 0.019). Mean total thyroid volume was significantly smaller in IEI patients than in controls (6.85 ± 2.92 mL vs. 10.52 ± 5.44 mL; p < 0.05).ConclusionsOur findings demonstrated that AITD is significantly more prevalent in IEI patients. Thyroid nodule frequency did not differ between groups. These findings support the routine incorporation of thyroid ultrasonography and autoantibody screening into IEI follow-up protocols. Larger multicenter prospective studies are warranted to confirm these observations across diverse IEI subtypes. Introduction Inborn errors of immunity (IEI), formerly classified as primary immunodeficiency disorders (PIDs), encompass a clinically and genetically heterogeneous spectrum of approximately 559 distinct genetic conditions characterized by dysregulated immune system function and development. Beyond their hallmark susceptibility to recurrent and severe infections, patients with IEI demonstrate a substantially elevated predisposition to diverse non-infectious complications, including allergic manifestations, autoimmune phenomena, autoinflammatory syndromes, lymphoproliferative disorders, and various malignancies [1]. Among these non-infectious sequelae, autoimmune diseases constitute the predominant complication, with autoimmune endocrinopathies—particularly thyroid autoimmunity—representing one of the most frequently documented manifestations [2–4]. The intricate bidirectional communication between the immune and endocrine systems occurs through multiple molecular and cellular pathways. Current evidence suggests two principal pathophysiological mechanisms underlying endocrine dysfunction in IEI: immune-mediated autoimmune destruction and direct pleiotropic effects of the causative genetic mutations on endocrine tissue development and function [5]. Autoimmune thyroid diseases (AITD) represent the most prevalent organ-specific autoimmune endocrinopathies in the general population, with Hashimoto’s thyroiditis (HT) and Graves’ disease (GD) accounting for the majority of cases [6, 7]. The pathogenesis of autoimmune thyroid diseases is characterized by complex immunological interactions, including T-cell-mediated immune dysregulation, polyclonal B-cell activation, and the generation of thyroid-specific autoantibodies — notably anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-Tg), and thyroid-stimulating hormone receptor antibodies (TRAb) [6–9]. Despite their well-established diagnostic utility, these autoantibodies remain undetectable in approximately 5–10% of affected individuals [10]. In serologically negative cases, thyroid ultrasonography (USG) assumes particular diagnostic relevance, with characteristic findings such as diffuse hypoechogenicity and parenchymal heterogeneity providing supportive evidence for the diagnosis of autoimmune thyroiditis. The entity known as seronegative chronic autoimmune thyroiditis (SN-CAT) encompasses patients who exhibit these typical sonographic features in the absence of detectable circulating thyroid autoantibodies. Clinically, SN-CAT may manifest as overt hypothyroidism, subclinical hypothyroidism, or, less commonly, as a euthyroid state with preserved thyroid function [11–13]. Beyond autoimmune pathology, thyroid nodules are remarkably common, with a prevalence of approximately 25% in the general population; however, this rate varies considerably based on age, sex, and the presence of relevant risk factors [14]. Despite the well-established association between IEI and autoimmune thyroid disease, comprehensive epidemiological data characterizing the frequency of AITD in this patient population remain limited. Moreover, studies systematically evaluating thyroid nodule frequency in IEI patients are particularly scarce [2, 4]. This knowledge gap is clinically significant, given that thyroid malignancy is identified in approximately 1–5% of thyroid nodules, and accumulating evidence demonstrates that autoimmune thyroid diseases confer an increased risk of thyroid carcinogenesis [15, 16]. Given these considerations, we aimed to determine the frequency of thyroid nodules and concomitant autoimmune thyroid diseases in a cohort of patients with adult IEI, thereby addressing a critical gap in the current literature. Materials and methods Study design and ethical approval This case-control study was conducted at the Adult Allergy and Immunology Clinic and the Endocrinology and Metabolism Clinic of Konya Meram Medical Faculty. The study protocol received approval from the Institutional Ethics Committee (approval number: 2023/ 4519). Written informed consent was obtained from all participants prior to enrollment in accordance with the Declaration of Helsinki principles. Study population This case-control study enrolled 40 patients diagnosed with inborn errors of immunity (IEI) according to the European Society for Immunodeficiencies (ESID) criteria [17], who were followed at the Allergy and Immunology outpatient clinic between 2023 and 2026, and 65 healthy subjects matched for age, and sex. Control subjects were defined as individuals who did not fulfill any diagnostic criteria for immunodeficiency. Patients and healthy subjects who were age under 18 years, diagnosis of seconder immunodeficiency and history of thyroid surgery were excluded from the study. Data collection Demographic data of the patients were retrieved from electronic medical records. Following an 8-hour overnight fasting period, blood samples were obtained from the patients, and serum levels of thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), anti-TPO, anti-Tg, TRAb levels (normal range, respectively, 0.27–4.20 mU/L, 0.93–1.70 ng/dl, 2-4.4 ng/dl, 0–34 IU/mL, 0-115 IU/mL, 0-1.75 u/L) were analyzed. TSH, fT4, fT3 levels were measured via chemiluminescent microparticle immunoassay and anti-TPO, anti-TG and TRAb levels were measured by chemiluminescent competitive immunoassay. To minimize the potential influence of passively transferred antibodies from immunoglobulin preparations on thyroid autoantibody measurements, blood samples were systematically obtained prior to scheduled immunoglobulin therapy in all patients. Infusion intervals varied according to the route of administration; patients receiving subcutaneous immunoglobulin (SCIG) were administered therapy every 7 days, whereas those receiving intravenous immunoglobulin (IVIG) received infusions every 21 days. Blood sampling was consistently timed to the pre-infusion period in both groups. Height (m) and weight (kg) of patients and controls were measured with underwear. Body mass index (BMI) was calculated using the weight(kg) /height square (m2) formula. All participants underwent comprehensive thyroid ultrasonographic examination performed by a single experienced endocrinologist using [LOGIQ 3 US device] with a 12 MHz linear transducer. Systematic assessment included documentation of thyroid gland dimensions, parenchymal echogenicity patterns, and identification of thyroid nodules. Nodule characteristics, including size, composition, echogenicity, margins, and presence of suspicious features, were recorded according to standardized reporting criteria. Thyroid volumes were calculated separately for each lobe using the elliptical shape volume formula (width x length x height x 0.52). Total thyroid volume was calculated by summing both thyroid lobe volumes. Lesions larger than 3 mm detected by USG were considered nodules. In patients with thyroid nodules, each thyroid nodule was categorized according to American Collage of Radiology -Thyroid Imaging Reporting and Data System (ACR-TIRADS) classification [18]. Fine needle aspiration biopsy (FNAB) was performed on patients with thyroid nodules in accordance with ACR-TIRADS recommendations. Cytological specimens were analyzed and classified using the Bethesda System for Reporting Thyroid Cytopathology [19]. In cases yielding nondiagnostic results (Bethesda Category I), repeat biopsy was performed within 3 months. The diagnosis of autoimmune thyroid disease was established by the presence of positive thyroid autoantibodies in conjunction with at least one of the following criteria: (1) thyroid USG features consistent with autoimmune thyroiditis, (2) thyroid function test abnormalities, or (3) patients receiving levothyroxine therapy [10, 20, 21]. Seronegative autoimmune thyroid disease was diagnosed in patients with negative thyroid autoantibodies who had typical ultrasonographic features of autoimmune thyroid disease, with or without normal thyroid function tests [11, 12]. Thyroid function status was classified based on biochemical criteria as follows: euthyroidism corresponded to serum TSH, fT3, and fT4 levels all within the laboratory reference range; overt hypothyroidism was characterized by an elevated serum TSH level above the upper limit of the reference range accompanied by a decreased fT4 level below the lower limit of normal; subclinical hypothyroidism referred to an elevated serum TSH concentration with fT3 and fT4 levels remaining within the normal reference range; subclinical hyperthyroidism was characterized by a subnormal serum TSH level below the lower limit of the reference range with normal fT3 and fT4 concentrations; and overt hyperthyroidism referred to a suppressed serum TSH level in conjunction with elevated fT3 and/or fT4 concentrations above the upper limit of normal [22, 23]. Statistical analysis Statistical analyses were performed using SPSS version 27.0 (IBM Corp., Armonk, NY, USA). Continuous variables were given as mean±standart deviation if the distribution was normal and as median with interquartile range (IQR) if the distribution was not normal. The Kolmogorov-Smirnov test was used to determine whether the data were normally distributed or not. Categorical variables are expressed as frequencies and percentages. Between-group comparisons of continuous variables were conducted using the independent samples t-test for normally distributed data or the Mann-Whitney U test for non-normally distributed data. Categorical variables were compared using the chi-square test or Fisher’s exact test. To evaluate potential associations between thyroid volume and clinical parameters, Spearman’s correlation analysis was performed. Correlation coefficients (r) and corresponding p-values are reported. For differences, a p-value < 0.05 was considered statistically significant for all analyses. Results Patient characteristics A total of 44 patients with IEI were initially identified, of whom 4 (2 women and 2 men) were excluded due to a history of thyroidectomy, yielding a final study cohort of 40 patients. These patients were matched according to sex and age with 65 healthy subjects. The mean BMI was similar between the IEI and control groups (24.76 ± 4.89 vs. 25.25 ± 3.17 kg/m², p = 0.276 ) with no statistically significant difference observed. Demographic and clinical characteristics of the study population are summarized in Table 1. Table 1Demographic and clinical characteristics of the study populationCharacteristicIEI Group (n = 40)Control Group (n = 65)p-valueAge (years) Mean ± SD36.92 ± 11.5738.30 ± 10.240.52* Range20–7222–66Sex, n (%)0.95† Male17 (42.5)28 (43.1) Female23 (57.5)37 (56.9)BMI (kg/m²) Mean ± SD24.76 ± 4.8925.25 ± 3.170.27*Disease duration (years) Median (IQR)7 (11.5)–BMI Body mass index, IEI Inborn errors of immunity, IQR Interquartile range, SD Standard deviation* Independent samples t-test; † Chi-square test Table 1Demographic and clinical characteristics of the study populationCharacteristicIEI Group (n = 40)Control Group (n = 65)p-valueAge (years) Mean ± SD36.92 ± 11.5738.30 ± 10.240.52* Range20–7222–66Sex, n (%)0.95† Male17 (42.5)28 (43.1) Female23 (57.5)37 (56.9)BMI (kg/m²) Mean ± SD24.76 ± 4.8925.25 ± 3.170.27*Disease duration (years) Median (IQR)7 (11.5)–BMI Body mass index, IEI Inborn errors of immunity, IQR Interquartile range, SD Standard deviation* Independent samples t-test; † Chi-square test Demographic and clinical characteristics of the study population BMI Body mass index, IEI Inborn errors of immunity, IQR Interquartile range, SD Standard deviation * Independent samples t-test; † Chi-square test According to the International Union of Immunological Societies (IUIS) classification, the vast majority had predominantly antibody deficiencies (90%, n = 36). The patient distribution is shown in Fig. 1. Immunoglobulin replacement therapy was administered all patients of whom 87.5% received IVIG and %12.5 SCIG. No patients had undergone bone marrow transplantation. Fig. 1Distribution of patients according to IUIS classification (n = 40). IEI: inborn errors of immunity; CVID: common variable immunodeficiency; XLA: X-linked agammaglobulinemia; IUIS: International Union of Immunological Societies. IEI categories based on: Bousfiha AA, Jeddane L, Moundir A, et al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. Journal of Human Immunity. 2025;1(1) Distribution of patients according to IUIS classification (n = 40). IEI: inborn errors of immunity; CVID: common variable immunodeficiency; XLA: X-linked agammaglobulinemia; IUIS: International Union of Immunological Societies. IEI categories based on: Bousfiha AA, Jeddane L, Moundir A, et al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. Journal of Human Immunity. 2025;1(1) Thyroid disorders Thyroid nodules were detected in 5 of 40 patients (12.5%) in the IEI group and in 14 of 65 participants (21.5%) in the control group. Although the prevalence appeared numerically lower in the IEI cohort, this difference did not reach statistical significance (p = 0.243). The presence of nodules was significantly more prevalent in females in IEI group (p = 0.040). However, no significant sex-based difference was observed in the control group (p = 0.061). In the IEI group, all patients with detected nodules had common variable immunodeficiency (CVID). The number of patients with TR1, TR2, TR3, TR4 and TR5 nodules in the IEI group was 1, 2, 1, 1, 0 respectively. In the control group, the number of subjects with TR1, TR2, TR3, TR4 and TR5 nodules was 2, 9, 3, 0, 0 respectively. FNAB was performed in one patient from the IEI group and two patients from the control group. Cytological examination revealed benign in both patients in the control group, whereas following two consecutive FNAB results in the IEI group were non-diagnostic. Surgical intervention was recommended to the patient; however, the patient declined the proposed procedure. The thyroid nodule characteristics are presented in Table 2. Table 2Thyroid nodule characteristics in the IEI and control groupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceThyroid nodules, n (%)5 (12.5)14 (21.5)0.243NS‡Nodule prevalence by sex — IEI group (F/M, %)100/0—0.040*‡Nodule prevalence by sex — Control group (F/M, %)—64.3/35.70.061NS†TIRADS (TR1/TR2/TR3/TR4/TR5), n1/2/1/1/02/9/3/0/00.243—‡NS not statistically significant, F female, M male, IEI Inborn error immunity, TIRADS Thyroid Imaging Reporting and Data System * p < 0.05. † Fisher’s exact test; ‡ Chi-square test Table 2Thyroid nodule characteristics in the IEI and control groupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceThyroid nodules, n (%)5 (12.5)14 (21.5)0.243NS‡Nodule prevalence by sex — IEI group (F/M, %)100/0—0.040*‡Nodule prevalence by sex — Control group (F/M, %)—64.3/35.70.061NS†TIRADS (TR1/TR2/TR3/TR4/TR5), n1/2/1/1/02/9/3/0/00.243—‡NS not statistically significant, F female, M male, IEI Inborn error immunity, TIRADS Thyroid Imaging Reporting and Data System * p < 0.05. † Fisher’s exact test; ‡ Chi-square test Thyroid nodule characteristics in the IEI and control groups NS not statistically significant, F female, M male, IEI Inborn error immunity, TIRADS Thyroid Imaging Reporting and Data System * p < 0.05. † Fisher’s exact test; ‡ Chi-square test Ultrasonographic assessment of thyroid parenchymal echotexture revealed heterogeneous parenchyma in 12 of 40 IEI patients (30.0%) compared to 11 of 65 controls (16.9%). Although the frequency of heterogeneous parenchyma was numerically higher in the IEI group, this difference did not achieve statistical significance (p = 0.11). Subgroup analysis by sex within the IEI cohort revealed a significant sex-based difference in parenchymal characteristics. Heterogeneous thyroid parenchyma was significantly more prevalent among female patients compared to male patients with IEI (p = 0.03). This sex-related difference was not observed in the control group (p = 0.861). Total thyroid volume was determined as 6.85 ± 2.92 ml in the IEI group and 10.52 ± 5.44 ml in the control group. A statistically significant difference was found between the two groups in terms of thyroid volumes (p = 0.000) (Table 3). There was no statistically significant correlation between thyroid volume and disease duration (r = 0 0.232, p = 0.149 ). Table 3Comparison of thyroid sonographic features between the IEI and control GroupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceHeterogeneous parenchyma, n (%)12 (30.0%)11 (16.9%)0.110NS‡Heterogeneous parenchyma by sex — IEI group (F/M, n)10/2—0.030*‡Heterogeneous parenchyma by sex — Control group (F/M, n)—6/50.861NS†Mean total thyroid volume (mL, mean ± SD)6.85 ± 2.9210.52 ± 5.440.000*§NS not statistically significant, F female, M male, SD standard deviation, IEI Inborn errors of immunity† Fisher’s exact test; ‡ Chi-square test; § Independent samples t-test. * p < 0.05 Table 3Comparison of thyroid sonographic features between the IEI and control GroupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceHeterogeneous parenchyma, n (%)12 (30.0%)11 (16.9%)0.110NS‡Heterogeneous parenchyma by sex — IEI group (F/M, n)10/2—0.030*‡Heterogeneous parenchyma by sex — Control group (F/M, n)—6/50.861NS†Mean total thyroid volume (mL, mean ± SD)6.85 ± 2.9210.52 ± 5.440.000*§NS not statistically significant, F female, M male, SD standard deviation, IEI Inborn errors of immunity† Fisher’s exact test; ‡ Chi-square test; § Independent samples t-test. * p < 0.05 Comparison of thyroid sonographic features between the IEI and control Groups NS not statistically significant, F female, M male, SD standard deviation, IEI Inborn errors of immunity † Fisher’s exact test; ‡ Chi-square test; § Independent samples t-test. * p < 0.05 Autoimmune thyroid disease was detected in 18 (45%) patients in the IEI group, compared to 15 (23.1%) patients in the control group. Autoimmune thyroid disease was found to be significantly more frequent in the IEI group (p = 0.019). All patients with AITD were diagnosed with HT and no cases of GD were identified. Seropositive autoimmune thyroid disease was detected in 11 patients (27.5%) in the primary immunodeficiency group and in 11 patients (16.9%) in the control group. No statistically significant difference was observed between the two groups with respect to seropositive autoimmune thyroid disease (p = 0.196). Seropositive autoimmune thyroid disease was higher in female participants compared to males (28.3% vs. 11.1%, respectively; p = 0.032) ın the IEI group (n = 40), seropositivity was more prevalent in female patients compared to males (39.1% vs. 11.8%, respectively), although this difference did not reach statistical significance (p = 0.079). Similarly, in the control group (n = 65), seropositivity was more frequently observed in females than in males (21.6% vs. 10.7%, respectively), with no statistically significant difference detected (p = 0.326). The autoimmune thyroid diseases of the patients are presented in Table 4. No significant difference was found in TSH levels between the two groups (p = 0.404). The IEI group demonstrated significantly higher fT3 levels, while the control group exhibited significantly higher fT4 levels. (p = < 0.01, p = < 0.01, respectively). In the IEI group, anti-TPO antibodies were positive in 7 patients (17.5%), anti-Tg antibodies in 5 patients (12.5%), and TRAb in 7 patients (17.5%). In the control group, anti-TPO antibodies were positive in 7 patients (10.8%), anti-Tg antibodies in 6 patients (9.2%), and TRAb in 6 patients (9.2%). No statistically significant difference was found between the two groups regarding anti-TPO, anti-Tg, and TRAb positivity (p = 0.324, p = 0.745, and p = 0.235, respectively) (Table 5). Table 4Autoimmune thyroid diseases in the IEI and control groupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceAutoimmune thyroid disease, n (%)18 (45.0)15 (23.1)0.019*†Sex, n (%)0.029*† Female14 (77.8)10 (66.7) Male4 (22.2)5 (33.3)Seropositive autoimmune thyroid disease, n (%)11 (27.5)11 (16.9)0.196NS†Sex, n (%)0.032*† Female9 (81.8)8 (72.7) Male2 (12.2)3 (27.3)NS not statistically significant, AITD Autoimmune thyroid disease, IEI Inborn errors of immunity † Chi-square test. * p < 0.05 Table 4Autoimmune thyroid diseases in the IEI and control groupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceAutoimmune thyroid disease, n (%)18 (45.0)15 (23.1)0.019*†Sex, n (%)0.029*† Female14 (77.8)10 (66.7) Male4 (22.2)5 (33.3)Seropositive autoimmune thyroid disease, n (%)11 (27.5)11 (16.9)0.196NS†Sex, n (%)0.032*† Female9 (81.8)8 (72.7) Male2 (12.2)3 (27.3)NS not statistically significant, AITD Autoimmune thyroid disease, IEI Inborn errors of immunity † Chi-square test. * p < 0.05 Autoimmune thyroid diseases in the IEI and control groups NS not statistically significant, AITD Autoimmune thyroid disease, IEI Inborn errors of immunity † Chi-square test. * p < 0.05 Table 5Comparison of thyroid function and autoantibody tests between the IEI and control groupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceThyroid function tests TSH (mU/L)2.17(0.35–6.51)1.86 (0.24–8.88)0.404‡NS fT3 (ng/dl)2.85 ± 0.541.18 ± 0.16< 0.01†* fT4 (ng/dl)1.17 ± 0.202.60 ± 0.61<0.01†*Thyroid autoantibody tests Anti-TPO, n (%)7 (17.5)7 (10.8)0.324§NS Anti-Tg, n (%)5 (12.5)6 (9.2)0.745†NS TRAb, n (%)7 (17.5)6 (9.2)0.235†NSNS Not statistically significant, Anti-TPO Anti-thyroid peroxidase antibody, Anti-Tg Anti-thyroglobulin antibody, TRAb Thyrotropin receptor antibody, fT3 free triiodothyronine, fT4 free thyroxine, TSH thyroid-stimulating hormone, IEI inborn errors of immunity* p < 0.05. † Independent samples t-test ‡ Mann-Whitney U § Chi-square test Table 5Comparison of thyroid function and autoantibody tests between the IEI and control groupsParameterIEI Group(n = 40)Control Group(n = 65)p valueSignificanceThyroid function tests TSH (mU/L)2.17(0.35–6.51)1.86 (0.24–8.88)0.404‡NS fT3 (ng/dl)2.85 ± 0.541.18 ± 0.16< 0.01†* fT4 (ng/dl)1.17 ± 0.202.60 ± 0.61<0.01†*Thyroid autoantibody tests Anti-TPO, n (%)7 (17.5)7 (10.8)0.324§NS Anti-Tg, n (%)5 (12.5)6 (9.2)0.745†NS TRAb, n (%)7 (17.5)6 (9.2)0.235†NSNS Not statistically significant, Anti-TPO Anti-thyroid peroxidase antibody, Anti-Tg Anti-thyroglobulin antibody, TRAb Thyrotropin receptor antibody, fT3 free triiodothyronine, fT4 free thyroxine, TSH thyroid-stimulating hormone, IEI inborn errors of immunity* p < 0.05. † Independent samples t-test ‡ Mann-Whitney U § Chi-square test Comparison of thyroid function and autoantibody tests between the IEI and control groups NS Not statistically significant, Anti-TPO Anti-thyroid peroxidase antibody, Anti-Tg Anti-thyroglobulin antibody, TRAb Thyrotropin receptor antibody, fT3 free triiodothyronine, fT4 free thyroxine, TSH thyroid-stimulating hormone, IEI inborn errors of immunity * p < 0.05. † Independent samples t-test ‡ Mann-Whitney U § Chi-square test In the IEI group, euthyroidism was detected in 35 patients (87.5%) and subclinical hypothyroidism in 5 patients (12.5%). In the control group, euthyroidism was present in 60 patients (92.3%), subclinical hyperthyroidism in 2 patients (3.1%), subclinical hypothyroidism in 2 patients (3.1%), and overt hypothyroidism in 1 patient (1.5%). All patients receiving levothyroxine treatment were euthyroid. Subgroup analysis of IEI diagnoses among patients with thyroid pathology revealed that CVID was the predominant underlying immunodeficiency. Specifically, 16 of 18 patients with AITD had CVID, with the remaining two cases comprising one patient with congenital neutropenia and one with inflammasomopathy. Notably, all patients with seropositive AITD and all patients with subclinical hypothyroidism carried a diagnosis of CVID, underscoring the particular predisposition of this subtype to autoimmune thyroid complications. Discussion In our study, we compared 40 patients with IEI and 65 healthy subjects in terms of thyroid nodules and autoimmune thyroid diseases frequency. To our knowledge, this is the first cross-sectional, controlled study to systematically assess thyroid nodule frequency in patients with adult IEI using specialist-performed ultrasonography. Our principal findings reveal that the prevalence of thyroid nodules did not differ significantly between IEI patients and healthy controls and, that autoimmune thyroid disease demonstrated a higher prevalence in the IEI cohort. Several studies have reported the prevalence of endocrine disorders in patients with primary immunodeficiency [2, 24]. Nevertheless, studies specifically assessing this in the context of thyroid diseases are limited in number [25]. In a study conducted in Japan evaluating endocrine complications in 923 patients with primary immunodeficiency, endocrine disorders were detected in 23 (5.3%) of the patients. The prevalence of endocrine diseases was found to be higher compared to the general population, with hypoparathyroidism reported as the most common endocrine disorder. Non-autoimmune hypothyroidism was detected in 7 patients [26]. In a study involving 84 patients with pediatric IEI patients, thyroid disease was the most common endocrinopathy. Thyroid disease was diagnosed in 26 (30.9%) patients (17 female, 9 male):20 (23.8%) with AITD and 6 (%7.1) with non-autoimmune hypothyroidism [27]. These data collectively suggest that thyroid involvement constitutes an important and underappreciated complication of primary immunodeficiency across age groups. Extensive literature indicates a higher prevalence of autoimmune diseases in subtypes of primary immunodeficiency, particularly in patients with common variable immunodeficiency (CVID) [28–30]. In our study, all of the patients presenting with thyroid nodules had an underlying diagnosis of CVID. This finding may reflect either a disease-specific predisposition driven by the underlying immune dysregulation associated with CVID, or simply the high representation of CVID cases within our patient cohort. Further studies with larger and more diverse patient populations are needed to clarify this relationship. Thyroid nodules are common in the general population, with prevalence rates ranging from 19% to 68% depending on the detection modality and the demographic characteristics of the study population. Ultrasonographic surveys conducted in iodine-sufficient regions typically report prevalence figures in the range of 20–35% [31–33]. In our control group, the prevalence of thyroid nodules was 21.5%, which is consistent with this reference range. Notably, the IEI group exhibited a numerically lower nodule prevalence of 12.5%. One potential explanation for this observation may relate to the altered immune surveillance mechanisms characteristic of IEI. In immunocompetent individuals, chronic low-grade inflammatory processes and autoimmune stimulation of thyroid tissue — mediated through pro-inflammatory cytokines produced by T and B lymphocytes — are thought to contribute to nodule formation over time [34]. However, in the context of PID — where B-cell differentiation defects and impaired humoral immunity predominate [35] — this inflammatory milieu may be fundamentally different, potentially attenuating rather than promoting nodular thyroid disease. Furthermore, the potential influence of long-term intravenous immunoglobulin (IVIG) replacement therapy — the cornerstone of CVID management — on thyroid nodule formation remains unknown and has not been systematically investigated to date. Notably, all patients in our cohort were receiving IVIG therapy at the time of evaluation, a factor that may have confounded the observed thyroid nodule prevalence and warrants consideration in the interpretation of our findings. Alternatively, the relatively small sample size of the present study may have limited the statistical power to detect a true difference in nodule prevalence between groups, and larger prospective studies are warranted to confirm or refute this observation. In a study retrospectively evaluating 40 patients with primary immunodeficiency for endocrinopathy, a single endocrinopathy was detected in 13 patients, while multiple endocrinopathies were identified in 5 patients. Among the endocrinopathies, thyroid diseases were the most frequently detected. Regarding thyroid diseases, thyroid nodules were found in 6 patients (15%), Graves’ disease in 1 patient, hypothyroidism in 5 patients, and secondary hypothyroidism in 1 patient. Among patients with thyroid nodules, 4 were male, and 2 were female. In this study, unlike our study, thyroid nodules were more frequently detected in male patients [2]. The reason for this discrepancy is unclear, but may reflect differences in IEI subtype distribution, disease severity, or hormonal interactions between immune dysregulation and thyroid biology. Thyroid nodules are known to be more prevalent in women in the general population [16], and our findings suggest this predisposition may be amplified in the context of primary immunodeficiency. In a Korean cohort of 130 patients with immunodeficiency, thyroid disease emerged as the most prevalent endocrine disorder (15/130), although thyroid nodule prevalence was not systematically reported [24]. Another retrospective study assessing autoimmune thyroid diseases in 45 adult patients with primary immunodeficiency identified autoimmune thyroiditis in seven patients and seronegative immune thyroiditis in one patient [25]. In their cohort, thyroid nodules were documented in only two patients among those with available ultrasonography data. These findings highlight the variable prevalence of thyroid pathology across different cohorts of patients with primary immunodeficiency. One of the most striking findings of this study was the significantly higher prevalence of autoimmune thyroid disease in the IEI group. Our finding of a 45.0% prevalence of AITD in IEI patients is substantially higher than figures reported in earlier retrospective series and control group [36]. Durmaz et al. identified autoimmune thyroiditis in 7 of 45 adult patients with primary immunodeficiency (15.6%) and noted female and seropositive AITD predominance, consistent with our observations [25]. A cohort study by Quinti et al. evaluating 92 IEI patients reported AITD as the most frequently detected autoimmune disorder (7/92; 7.6%) [4]. The considerably higher rate observed in the present study may be attributable to the study design, the systematic measurement of thyroid autoantibodies and thyroid ultrasonography in all participants, and the higher proportion of CVID patients, who carry an intrinsically elevated risk for autoimmune comorbidities. These methodological differences highlight that retrospective studies likely underestimate the true burden of AITD in IEI populations. This observation is consistent with the well-established concept of immune dysregulation in IEI, wherein disrupted central and peripheral tolerance mechanisms predispose affected individuals to autoimmunity despite global immunodeficiency. The paradox of concurrent immunodeficiency and autoimmunity is most paradigmatically illustrated in common variable immunodeficiency (CVID), which accounted for the majority of IEI diagnoses in our cohort and is recognized as a high-risk condition for organ-specific autoimmune diseases including autoimmune thyroiditis [37]. Dysregulated T-regulatory cell function, impaired B-cell receptor signaling are among the proposed mechanistic drivers of thyroid autoimmunity in this setting [38]. Our findings reinforce the clinical importance of routine thyroid antibody and thyroid USG screening in patients with primary immunodeficiency. A novel and previously unreported finding in our study was the significantly smaller thyroid volume in IEI patients compared with healthy subjects (6.85 ± 2.92 mL vs. 10.52 ± 5.44 mL). Reduced thyroid volume in the context of elevated thyroid autoantibody titers may reflect a degree of chronic autoimmune atrophic thyroiditis. Alternatively, the long-term use of intravenous immunoglobulin (IVIG)—administered in 87.5% of our patients—could theoretically interfere with thyroid autoantibody levels and thyroid function, as IVIG preparations contain polyclonal anti-idiotypic antibodies capable of neutralizing pathogenic autoantibodies [39]. The net clinical effect of IVIG on thyroid morphology, however, has not been systematically investigated and remains an open research question. The absence of a statistically significant difference in TSH levels between the two groups, higher fT3 levels observed in the IEI group, alongside significantly higher fT4 levels in the control group. This fT3/fT4 dissociation may reflect enhanced peripheral conversion of T4 to T3, potentially mediated by alterations in deiodinase enzyme activity driven by the chronic inflammatory milieu and dysregulated cytokine profiles characteristic of inborn errors of immunity. In this regard, proinflammatory cytokines such as IL-1β and IL-6 have been shown to directly modulate both type 1 and type 2 deiodinase activity, thereby influencing the rate of peripheral T4-to-T3 conversion independently of TSH-mediated regulation [40]. The possibility of non-thyroidal illness syndrome (euthyroid sick syndrome) as an alternative explanation for the observed fT3/fT4 dissociation was carefully considered. However, all patients were clinically stable at the time of blood sampling, with no evidence of active infection, acute illness, or hospitalization, rendering this diagnosis unlikely. The observed pattern is therefore more consistent with chronic low-grade immune dysregulation and altered deiodinase activity rather than an acute non-thyroidal illness response. Regarding thyroid autoantibody profiles, no statistically significant differences were observed between the PID and control groups with respect to anti-TPO, anti-Tg, or TRAb positivity. At first glance, this finding may appear to suggest a comparable burden of thyroid autoimmunity across both groups; however impaired antibody production resulting from defects in B cell differentiation and function, the absence of autoantibodies in CVID patients may obscure the serological diagnosis of autoimmune diseases, as autoantibody generation itself may be attenuated in this population [29, 30]. Negative autoantibody results in these patients cannot reliably exclude autoimmune thyroid disease. However, a critical methodological consideration that fundamentally complicates the interpretation of thyroid autoantibody results in our cohort relates to the universal exposure of our patients to long-term IVIG replacement therapy. It is therefore plausible that the anti-TPO, anti-Tg, and TRAb positivity rates observed in our PID cohort may be overestimated due to passive antibody transfer via IVIG. In either case, the net effect of long-term IVIG therapy on thyroid autoantibody levels in PID patients remains uncertain, and our results should be interpreted with this limitation in mind. Supporting this notion, in a cohort of 81 CVID patients, anti-TPO antibodies were among the most frequently detected autoantibodies, and latent autoimmunity — defined as the presence of autoantibodies without clinically manifest autoimmune disease — was documented in a subset of patients, highlighting the importance of longitudinal serological monitoring in this population [41]. In light of these considerations, both false-negative and false-positive autoantibody results are plausible in this population. These observations emphasize the imperative for future studies to adopt more rigorous methodological frameworks, thereby enhancing the reliability and clinical interpretability of thyroid autoimmunity data in patients with inborn errors of immunity. With respect to nodule characteristics, the distribution of TIRADS categories in both groups was reassuring, with the majority of nodules classified as TIRADS 2 or 3 — corresponding to benign or low-suspicion lesions — and no TIRADS 5 nodules identified in either group. FNAB was performed in one IEI patient and two control patients. In contrast, the single IEI patient who underwent FNAB yielded non-diagnostic results on two consecutive attempts, leading to a surgical recommendation that the patient ultimately declined. This case merits careful consideration within the broader oncological context of CVID. Among 250 CVID patients in a multicenter registry, 15.26% were diagnosed with cancer during follow-up, with non-Hodgkin B-cell lymphoma being the most frequent malignancy; thyroid cancer was also documented among the solid organ malignancies identified in this cohort, and immune dysregulation was identified as an independent risk factor for cancer development. These observations emphasize that thyroid nodule surveillance should be performed carefully and consistently in patients with CVID. Ultrasonographic assessment of thyroid parenchymal echotexture revealed heterogeneous parenchyma in 30.0% of IEI patients compared to 16.9% of controls. Heterogeneous thyroid echotexture is a well-recognized sonographic hallmark of autoimmune thyroid disease, most commonly reflecting the lymphocytic infiltration, fibrosis, and architectural disruption of the glandular parenchyma characteristic of Hashimoto’s thyroiditis [10]. In the context of PID, where immune dysregulation coexists with impaired humoral immunity, subclinical inflammatory processes directed against thyroid tissue may manifest ultrasonographically before overt serological or clinical evidence of autoimmune thyroid disease becomes apparent. A particularly noteworthy finding was the statistically significant sex-based difference in parenchymal heterogeneity observed within the IEI cohort. This observation is consistent with the well-established female predominance in autoimmune thyroid disease in the general population. This suggests that the superimposition of immune dysregulation inherent to PID upon the already heightened baseline autoimmune susceptibility of the female immune system may create a synergistic milieu that preferentially promotes subclinical thyroid inflammation in women with IEI. These findings collectively suggest that female patients with IEI may represent a particularly high-risk subgroup for the development of subclinical autoimmune thyroid pathology, warranting closer ultrasonographic and serological monitoring in clinical practice. This study has certain limitations. Its single-center design and small sample size limit the generalizability and statistical power of our findings. The baseline values of thyroid function tests and thyroid autoantibodies at diagnosis, as well as their changes during disease progression, are unknown. Nearly all patients in the study were receiving IVIG therapy, and the potential effects of IVIG on thyroid autoimmunity and nodule formation remain unclear. The heterogeneity of IEI diagnoses within our cohort precluded meaningful subgroup analyses by specific immunodeficiency type due to limited numbers in each category. Different IEI subtypes may have varying propensities for thyroid complications based on their underlying molecular defects and patterns of immune dysregulation, but our study was insufficiently powered to explore these relationships. Notwithstanding these limitations, the present study has important strengths. All thyroid ultrasonographic examinations were performed by an experienced endocrinologist using a standardized protocol, minimizing inter-observer variability. This is the first cross-sectional study to evaluate thyroid nodule prevalence in IEI using systematic ultrasonography, and the high rate of AITD (45%) identified herein carries direct clinical implications. Our findings support the routine incorporation of thyroid ultrasonography and thyroid autoantibody screening into the follow-up protocols of patients with IEI, particularly those with CVID. Early identification of AITD may allow timely intervention and prevent progression to overt hypothyroidism or hyperthyroidism, with consequent improvements in quality of life in this already-burdened patient population. Our findings highlight the need for larger, multicenter prospective studies with sufficient statistical power to definitively characterize thyroid pathology prevalence in IEI populations. Such investigations should include: (1) stratification by specific IEI subtypes to identify differential thyroid disease risks; (2) longitudinal assessment to evaluate temporal relationships and disease progression; (3) evaluation of potential confounding factors including IVIG therapy, concomitant medications, and disease severity; (4) molecular studies to elucidate mechanistic links between specific genetic defects and thyroid dysfunction; and (5) assessment of clinical outcomes including thyroid malignancy rates and response to standard thyroid treatments. Conclusion In conclusion, this study demonstrates a significantly elevated prevalence of autoimmune thyroid disease in patients with inborn errors of immunity, alongside a novel finding of markedly reduced thyroid volume — observations that add meaningful new dimensions to our understanding of thyroid pathology in this population. Thyroid nodule frequency, by contrast, did not differ significantly from that of healthy controls; nevertheless, the numerically lower prevalence observed in IEI patients represents a hypothesis-generating finding that the present study was likely underpowered to confirm, underscoring the need for larger multicenter investigations. Given that CVID constituted the predominant diagnosis in our cohort, the present findings are particularly well-substantiated for this subtype, while their applicability to the full spectrum of IEI remains an important avenue for future investigation. Taken together, these results reinforce the clinical imperative for systematic thyroid evaluation — encompassing both ultrasonography and autoantibody profiling — in the routine follow-up of patients with primary immunodeficiency.